COMPASS Pathways (CMPS) Announces Up to $285 Million Private Placement
Transaction led by healthcare specialist investors, TCGX and Aisling Capital
$125 million financing upfront with up to an additional $160 million tied to exercise of...
Billionaire, Point 72’s Steve Cohen, Continues to Support Psychedelic Research.
Cohen Psychedelic Research & Health Initiative
Cohen Foundation Awards $5 Million for MDMA Therapy Approval
Millions of Americans suffer from depression, anxiety, addiction, post-traumatic stress disorder...
Psycheceutical’s (BWVI) NeuroDirect™ Ketamine can Help Alleviate Headaches and Migraines Within Minutes, With no...
Photo MAPS Founder Rick Doblin visits Psycheceutical's Chief Visionary Officer Mike 'Zappy' Zapolin, CEO Chad Harman at the company's lab and tests NeuroDirect™ Ketamine....
Psycheceutical Bioscience (BWVI) Secures Funding for Clinical Trials
Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD.
Company raises $1.3M USD convertible note from Cantheon Capital for in-human trials...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical...
Video: New Topical Drug Delivery System, NeuroDirect™
Must Watch Video. Topical Application to Improve Delivery of FDA-Approved Drugs.
https://youtu.be/2CGT7P9QEvo
Can this be used for Ketamine treatments? Time will tell, as they are...
Topical PTSD Drug Poised for Human Trials.
In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid and psychedelic...
Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.
Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin
We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our Favorite.
We launched the Psychedelic Stock Review...
Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?
After dropping 94% from post IPO high from $19.45, a loss exceeding $3 billion and change, ATAI is in the early stages of recovery (in our opinion)...
The Ketamine Endgame. Silo Pharmaceutical (SILO).
James Kuo, M.D. the Vice President of R&D for Silo Pharma (SILO) will speak at the 3rd Annual Psychedelic Therapeutics and Drug Development Conference.
Dr....
Latest article
A Turnaround at Mitesco Coming? Mitesco Moves Into Mini-Data Centers.
Last Round (turnaround that is) worked great, back in 2019, Trading From $0.02 to $0.50. And no, we Didn't Sell a Single Share (waa)....
Mining Legends: Dr Sergei Diakov
Meet Dr. Sergei Diakov. Most investors have never heard his name, but global mining giants like BHP, Anglo American, and AngloGold Ashanti know exactly...
BCM Resource Corp (B.V), We’re Up 137% in one Week!
Well That's Working out Quite Well..
When we got the news the other day that Mining Legend Dr. Sergei Diakov, reported some rather excellent numbers...
